Technology Development Recent Happenings

Inventors Recognition Program

United States Patent 9,968,693 was issued on May 15, 2018 for Small molecule imaging of fungi by positron emission tomography scanning. NIAID inventors: Dr Peter Richard Williamson, Dr Dale KiesewetterDr Jin Qui

United States patent 9,890,369 was issued on February 13, 2018 for Cytolethal distending toxin subunit B conjugated or fused to Bacillus anthracis toxin lethal factor. Dr Steve Leppla 

United States patent 9,957,486 was issued on May 1, 2018 for Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization. NIAID inventors: Dr Peter L CollinsDr Ursula J. Buchholz, Dr Cyril Le Nouen

United States patent 10,000,556 was issued on June19, 2018 for Single-domain V.sub.HH antibodies directed to norovirus GI.1 and GII.4 and their use.  NIAID inventors: Dr Karin Bok, Dr Lisbeth Kim Green, Stanislav Sosnovtsev 

Recent Patents

United States Patent 9,968,693 was issued on May 15, 2018 for Small molecule imaging of fungi by positron emission tomography scanning.  NIAID inventors: Dr Peter Richard Williamson, Dr Dale u kyKiesewetter ; Dr Jin Qui

United States patent 9,896,509 was issued on February 20, 2018 for Use of antagonists of the interaction between HIV GP120 and .alpha.4.beta.7 integrin  NIAID inventors: James Arthos, Ph.D.,  Claudia Cicala, Ph.D., Anthony S. Fauci, M.D.

United States patent 9,884,104 was issued on February 6, 2018 for Live attenuated virus vaccines for la crosse virus and other bunyaviridae.  NIAID inventors: Stephen S. Whitehead, Ph.D.Richard S. Bennett, Ph.D.

United States patent, 9,580,492 was issued on January 30, 2018 for Cytolethal distending toxin subunit B conjugated or fused to Bacillus anthracis toxin lethal factor.  NIAID inventor: Stephen Leppla, Ph.D.

United States patent 9,850,468 was issued on December 26, 2017, for Infectious hepatitis E virus genotype 3 recombinants.  NIAID inventors: Hanh T. Nguyen

United States patent 9,845,350 was issued on December 19, 2017, for Monoclonal antibodies that react with the capsule of bacillus anthracis. NIAID inventors: Zhaochun Chen, Ph.D., Joanna Kubler-Kielb Ph.D.

Recent Collaborative Agreements

NIAID and Kephera Diagnostics, LLC. signed a human research collaboration agreement (hu-RCA) Development of a point-of-care test for Lyme disease that can be performed at the site of patient care to help clinicians to evaluate patients and improve care. NIAID principle investigator: Dr. Adriana Marques

NIAID and University of Glasgow signed a standard research collaboration agreement (RCA-S) to study the sequestration pattern of early/immature gametocyte stages in the bone marrow using Non-Human Primate (NHP) models. NIAID principle investigator: Dr. Thomas E. Wellems

NIAID and University of Washington signed a human research collaboration agreement (hu RCA) to evaluate virus-specific T cell responses in samples from patients presenting with severe or unusual viral infections. NIAID principle investigator: Dr. Jeffrey Cohen, MD

NIAID and Lumen Bioscience Inc. signed Use of Lumen Bioscience's protein expression technology with NIAID/VRC's influenza and HIV immunogens.  NIAID principle investigator: Dr. Barney Graham

NIAID and New York University School of Medicine (NYU) signed a human research collaboration agreement (Hu-RCA) to characterize the peanut allergic patients for their anaphylaxis risk and carry out the first characterization of IgE serum antibodies from isolated patients’ blood. NIAID principle investigator: Dr. Jeffrey Cohen, MD

NIAID and Lumen Bioscience Inc. signed a standard research collaboration agreement (RCA-S) for the use of protein expression technology with NIAID/VRC's influenza and HIV immunogens.  NIAID principle investigator: Dr. Barney Graham

NIAID and Scripps Research Institute (TSRI) signed a standard research collaboration agreement (RCA-S) to develop a universal influenza vaccine through characterization of neutralizing antibody-hemagglutinin structure.   NIAID principle investigator: Adrian Bernard McDermott  

NIAID and Duke University signed a human research collaboration agreement (Hu-RCA) on the effect of alpha globin on nitric oxide regulation in both asthma and vascular disease. NIAID principle investigators: Dr. Hans C. AckkermanDr. Parker Amy Ruhl, MD , Loretta Qu

NIAID and US Army Medical Research Institute of Infectious Diseases (USAMRIID) (DoD) signed a standard research collaboration agreement (RCA-S) to recreate (“rescue”) Ebola virus variant (EBOV) using plasmids encoding the EBOV genome.  NIAID principle investigator: Dr. Peter Jahrling 

NIAID and Cogen Therapeutics, Inc. signed a standard research collaboration agreement (RCA-S) to use antibody and antigen labeling techniques to image, detect, count, and sort cells according to their antigen specificity. NIAID principle investigator: Dr.Daniel Douek

NIAID and University of Oxford signed a standard research collaboration agreement (RCA-S) to design and test its adeno virus and VRC's peptide adjuvant nanoparticle vaccine. NIAID principle investigator: Dr. Robert Seder

NIAID and Avatar Medical, LLC signed a standard research collaboration agreement (RCA-S) to collaborate to develop reagents that will facilitate the development of RSV vaccine assays. NIAID principle investigator: Barney Graham, MD, PhD

NIAID and MockV Solutions signed a standard research collaboration agreement (RCA-S) for VPP to evaluate MockV's technology that is designed to reduce costs and technical hurdles for advancing experimental vaccines into clinical trials. NIAID principle investigator: Daniel Gowetski, PhD

Content last reviewed on June 28, 2018